Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 29;13:978092. doi: 10.3389/fimmu.2022.978092

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Shen, Zhong, He, Han and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Evaluation of the sensitivity to immunotherapy with MHPS (A) Oncoplot of gene mutations in the low- and high-risk groups. (B) The tumor burden of low- and high-risk groups. (C) Comparison of immunophenoscore (IPS) between low and high MHPS risk groups. (D–F) Expression of PD-1, PD-L1, CTLA-4 in low- and high-risk groups (G)Proportion of immunotherapy responsive and ineffective patients in low- and high-risk groups. SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response. (H) Different overall survival of patients with high or low MHPS score. (I) Comparison of risk score of patients with different immunotherapy responses.